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COST OF TREATMENT OF 
HYPERCHOLESTEROLAEMIA TO NHF GOALS
IN AUSTRALIA
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OBJECTIVE: To estimate the comparative cost-effective-
ness of atorvastatin and simvastatin. METHODS: A ran-
domized clinical trial set in general practice. Effectiveness
was measured by percentage reduction in total choles-
terol and percentage of patients achieving NHF targets.
The costs calculated in the study were hospital admis-
sions, emergency room/clinic visits, visits to GPs and spe-
cialists, tests/investigations, treatment of adverse events
and drug costs. RESULTS: Of the 691 patients in the
atorvastatin arm, 682 used health care resources. Of the
337 patients in the simvastatin arm, 332 used health care
resources. The monthly drug costs with atorvastatin was
$48.30 for 10mg, $66.93 for 20mg, with simvastatin at
$42.06 for 10 mg, $58.12 for 20mg. The average cost of
health care for atorvastatin and simvastatin was $460.48
and $490.11 respectively (p  0.47). Adverse events ac-
counted for 60% of all health care costs in the atorvasta-
tin group, 77% in the simvastatin group. The weighted
average monthly drug costs (WAMDC) after 6 weeks of
treatment were $48.30 for atorvastatin and $42.06 for
simvastatin. 38% of patients reached NHF target choles-
terol levels on atorvastatin, 25.5% on simvastatin. The
cost per responder was $1.27 with atorvastatin, $1.63
with simvastatin. After 12 weeks of treatment the
WAMDC was $59.53 for atorvastatin, $53.77 for sim-
vastatin with 47.5% and 33.8% response rates, respec-
tively. The incremental cost-effectiveness of an extra pa-
tient achieving target on atorvastatin was $0.50 at 6
weeks, $0.42 at 12 weeks, $0.26 at 18 weeks and $0.51
at 24 weeks. CONCLUSION: Atorvastatin achieved a
greater percentage reduction in total cholesterol per mg
than simvastatin, and was equally well tolerated. While
drug costs for atorvastatin were slightly higher, overall
health care costs were lower than for simvastatin. Ator-
vastatin was more cost-effective than simvastatin in
achieving NHF targets. The incremental cost-effective-
ness of atorvastatin suggests additional patients can
achieve NHF targets relatively inexpensively.
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OBJECTIVES: To determine the cost-effectiveness (CE)
of managing patient low density lipoprotein-cholesterol
(LDL-C) levels with exercise plus nutritional therapy and
exercise plus nutritional plus pharmacotherapy from the
Indian Health Service perspective. METHODS: A retro-
spective database analysis was performed on data col-
lected from a pharmacist managed Cardiovascular Risk
Reduction Program (CVCRRP) from March 1997
through October 1999. Patients received exercise plus
nutritional therapy (Group 1) or exercise plus nutritional
plus pharmacotherapy (Group 2). Effectiveness measures
included unit and percent LDL-C reduction from initial
to last recorded visit. Costs (fixed plus variable) and re-
imbursements were determined in terms of 1999 dollar
values through clinic staff interviews and billing records
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analysis. Average and incremental cost-effectiveness ra-
tios (ICE) were calculated. One-way sensitivity analyses
were performed varying pharmacist salary, medication
costs, and levels of reimbursement. RESULTS: Net cost-
per-patient in Group 1 (n  40) was $1,204; in Group 2
(n  32) was $1,432. Mean LDL-C reduction was
12.67mg/dl (Group 1) and 42.03mg/dl (Group 2). Mean
percent LDL-C reduction was 8.95% (Group 1) and
50.70% (Group 2). Average CE ratios were $95.01 (unit
LDL-C reduction) and $134.50 (percent LDL-C reduc-
tion) for Group 1; $34.07 (unit LDL-C reduction) and
$50.70 (percent LDL-C reduction) for Group 2. ICE ra-
tios for Group 2 versus Group 1 was $7.77 (unit LDL-C
reduction) and $11.82 (percent LDL-C reduction). The
obtained CE ratios were robust to sensitivity analysis pa-
rameters. CONCLUSIONS: The CVCRRP showed posi-
tive lipid management results for enrolled patients.
Group 2 (those including pharmacotherapy) interven-
tions were associated with higher costs and better LDL-C
outcomes. Group 2 interventions also resulted in more
favorable average CE ratios compared to Group 1. Study
results could be used to develop similar cardiovascular
risk reduction programs, expanding the clinical role of
the pharmacist and improving patient outcomes.
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OBJECTIVES: To evaluate the pharmacoeconomic prop-
erties of crataegus treatment compared to any other
treatment option of CHF at stage NYHA II, a prospective
3-year observational study has been conducted since
summer 1999. A cost-utility-analysis will be performed
to investigate, if crataegus treatment avoids rapid deterio-
ration with higher costs and lower HRQL. The results of
the first year are presented. METHODS: Open, non-ran-
domized observational cohort study. The first cohort
(Crataegus-Cohort, CC) comprises patients receiving cra-
taegus extract therapy of CHF. In the second cohort
(Standard-Cohort, SC) patients without crataegus but
any other treatment were observed. In 217 study centres
952 patients were included (CC: 588; SC: 364). For mea-
suring HRQL the EuroQoL-5D was used. The perspec-
tive of the German statutory health insurance funds and
the matched-pairs technique were applied. RESULTS:
No significant differences in physical condition and de-
mographic variables were detected between the matched
groups. HRQL (143 pairs) shows significant improve-
ment in both cohorts. The mean EuroQoL-VAS value for
the CC is 55.50 before and 67.13 after half-a-year (SC:
58.06 before and 66.78 after). Improvement of HRQL in
the CC is significantly higher (p  0.023). After one year,
an improvement of clinical symptoms were diagnosed in
both cohorts (79 pairs) but slightly higher in the CC with
no significance. Mean direct costs for CC patients
amounted to DM 1,373 in the first year whereas SC pa-
tients amounted to DM 1,551 with no significant differ-
ence (p  0.998, 98 pairs). Cost driving factors were
drug acquisition and physicians fees. CONCLUSIONS:
Even if the first analysis of the three-year-study indicates
comparable direct costs in both cohorts and suggests im-
proved HRQL in the CC further investigation in the sec-
ond and third period is mandatory.
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PATIENTS’ WILLINGNESS TO PAY FOR 
PHARMACIST MANAGED WARFARIN THERAPY 
AT COMMUNITY PHARMACIES
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OBJECTIVES: This study determined the benefits of
pharmacist managed warfarin therapy (PMWT) at com-
munity pharmacies by the contingent valuation (CV)
method. Benefits of PMWT in clinic have been docu-
mented. These are reduction in hospitalizations, emer-
gency room visits and thromboembolic events due to side
effects of inappropriate dosing and monitoring. How-
ever, these benefits were never measured from patient’s
perspective using CV method. This study elicited willing-
ness-to-pay (WTP) values for PMWT from community
pharmacy patients. METHOD: A self-administered 24
question CV survey was mailed to 2800 patients’ homes.
These patients were selected from files in community
pharmacies or a rural health plan. They were divided into
warfarin clinic (ex post) and non-warfarin clinic (ex ante)
groups. A payment card method with visual aid charts
elicited WTP values in form of out-of-pocket (OOP) ex-
pense and additional insurance premium (INS) for
PMWT with six probabilities for success (3 probabilities
for reduction in hospitalizations & 3 probabilities for re-
duction in blood clot events). RESULTS: Five hundred
and thirty patients (393 usable) responded. Overall mean
WTP values for PMWT in the form of OOP or INS were
significantly greater than zero. The monthly mean OOP
WTP amounts for 28% blood clot event reduction and
26% hospitalization reduction were $17.19  15.57 and
$19.26  17.56 respectively. The monthly mean INS
WTP for the same probabilities were $11.97  13.66 and
$12.66  14.63 respectively. Regression analysis identi-
fied that annual household income, selection of health
plan with PMWT and attitude towards the health plan’s
inclusion of PMWT were significant predictors for OOP
scheme and only annual household income and selection
of health plan with PMWT for INS scheme. CONCLU-
SION: Patients were able to assign WTP values to differ-
ent sizes of health gains. Range bias and inconsistency of
choice were detected from this sampled population.
